TranscriptsSwedenSep. 17, 2025 5:17 PM ETSwedish Orphan Biovitrum AB (publ) (SWOBY) Stock, BIOVF StockSWOBY, BIOVFSA Transcripts155.46K FollowersSwedish Orphan Biovitrum AB (publ) (OTCPK:SWOBY) NASP and Uncontrolled Gout Conference September 16, 2025 10:30 AM EDTCompany ParticipantsGuido Oelkers - CEO & PresidentMatthew Winfield - NASP Core Asset Team LeaderHerbert S. B. Baraf - Clinical Professor of MedicineRehan Azeem - Medical Development Lead, NASP programConference Call ParticipantsGonzalo Artiach Castanon - Danske Bank A/S, Research DivisionMattias Häggblom - Handelsbanken Capital Markets AB, Research DivisionMichael Leuchten - Jefferies LLC, Research DivisionKirsty Ross-Stewart - BNP Paribas Exane, Research DivisionPresentationGuido OelkersCEO & PresidentHello, everyone. This is Guido Oelkers, CEO of Sobi. We are delighted to welcome you to this call to discuss the NASP program after we have just received the acceptance of the filing package with FDA for uncontrolled gout.Please turn to Slide 2. We would like to remind you of the usual provisions on statements about expectations and projections of future events. With this said, please turn to Slide 3. I'm very pleased to have Dr. Herbert Baraf joining us today. He is Clinical Professor of Medicine at George Washington University, Associated clinical Professor at the University of Maryland and a Senior Clinical Adviser at the National Institute of Arthritis and Muscular and Skin Diseases at the National Institute of Health in Bethesda, Maryland.Dr. Baraf was a founding member of Arthritis and -- of the Arthritis and Dramatism associates one of the largest private rheumatology practices in United States, he has served as a principal investigator on over 400 clinical trials, including several significant therapeutic gout trials.We are also joined by Dr. Rehan Azeem, who is a medical development lead for the NASP program, here at Sobi as well as Matthew Winfield, our NASP core asset team leader at Sobi. Dr. Azeem has served in various medical research capacity on NASP, formerly SEL-212 for overRead more current SWOBY analysis and newsView all earnings call transcriptsCommentsRecommended For You